AUSTAR LIFESCIENCES LIMITED Austar Lifesciences Limited Stock
Equities
6118
KYG0632L1023
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.03 HKD | -9.65% |
|
-15.57% | -33.97% |
| Mar. 26 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 22 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
| Sales 2021 | 2.02B 278M 2.18B | Sales 2022 | 2.23B 308M 2.41B | Capitalization | 914M 126M 990M |
|---|---|---|---|---|---|
| Net income 2021 | 277M 38.27M 300M | Net income 2022 | 87M 12.02M 94.14M | EV / Sales 2021 | 3.09 x |
| Net cash position 2021 | 64.52M 8.91M 69.82M | Net Debt 2022 | 188M 26.03M 204M | EV / Sales 2022 | 0.49 x |
| P/E ratio 2021 |
22.8
x | P/E ratio 2022 |
10.5
x | Employees | 1,610 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 26.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -9.65% | ||
| 1 week | -15.57% | ||
| Current month | -16.26% | ||
| 1 month | -23.13% | ||
| 3 months | -40.46% | ||
| 6 months | -59.77% | ||
| Current year | -33.97% |
1 week
1.02
1.22
1 month
1.021.60
Current year
1.022.20
1 year
1.023.18
3 years
1.0230.90
5 years
1.0230.90
10 years
0.6730.90
| Managers | Title | Age | Since |
|---|---|---|---|
Kwok Keung Ho
CEO | Chief Executive Officer | 61 | 14-01-08 |
Yuk Kiu Mak
SEC | Corporate Secretary | - | 22-09-30 |
Xiang Di Tang
PRN | Corporate Officer/Principal | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lap Kei Cheung
BRD | Director/Board Member | 52 | 14-10-20 |
Oi Kin Leung
BRD | Director/Board Member | 50 | 17-10-20 |
Kwok Keung Ho
CEO | Chief Executive Officer | 61 | 14-01-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 1.14 | -0.87% | 41,000 |
| 24-04-12 | 1.15 | -4.96% | 123,000 |
| 24-04-11 | 1.21 | +0.83% | 4,452,000 |
| 24-04-10 | 1.2 | -1.64% | 343,000 |
| 24-04-09 | 1.22 | +1.67% | 30,000 |
Delayed Quote Hong Kong S.E., April 16, 2024 at 04:08 am EDT
More quotes
Austar Lifesciences Limited is principally engaged in the provision of integrated engineering solutions to pharmaceutical manufactures and research institutes and the manufacture and distribution of pharmaceutical equipment and consumables in China. The Company operates its business through six segments: liquid and bioprocess system segment, clean room and automation control and monitoring system segment, powder and solid system segment, good manufacturing practice (GMP) compliance service segment, life science consumables segment and distribution and agency of pharmaceutical equipment segment.
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -33.97% | 74.64M | |
| -1.38% | 189B | |
| -4.27% | 107B | |
| -4.48% | 67.81B | |
| +7.67% | 51.87B | |
| +16.04% | 46.67B | |
| -0.77% | 38.68B | |
| +6.84% | 27.73B | |
| +0.87% | 26.6B | |
| +4.68% | 26.34B |
- Stock Market
- Equities
- 6118 Stock
